---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: CORE-001"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: CORE-001. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 60 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence/core-001"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: CORE-001

<a id="heading-3.1.3"></a>

## 3.1.3 CORE-001

<a id="heading-3.1.3.1"></a>

### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

#### Study purpose in the ClinicalTrials.gov record

> “To evaluate the activity of intravesical administration of CG0070 and intravenous administration of Pembrolizumab in patients with tissue pathology-confirmed non-muscle invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease with carcinoma in situ (CIS) with or without Ta/T1 papillary disease.”

Source: [ClinicalTrials.gov NCT04387461](https://clinicaltrials.gov/study/NCT04387461)

<a id="topic-3.1.3.1-2"></a>

#### Study question in the published final results

> “In this phase 2 study, we assessed the potential synergistic efficacy between intravesical cretostimogene and systemic pembrolizumab in patients with BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ (CIS).”

Source: [Li et al. (2024a)](https://www.nature.com/articles/s41591-024-03025-3)

<a id="topic-3.1.3.1-3"></a>

#### Primary and secondary objectives in the clinical study protocol

> “Evaluate the complete response rate at 12 months of CG0070 combined with pembrolizumab in patients with BCG unresponsive carcinoma in situ (CIS) with or without concomitant high-grade Ta (TaHG) or T1 papillary disease”
> “Evaluate the safety of CG0070 combined with pembrolizumab”
> “Determine the complete response rate at any time on study”
> “Assess the duration of response (DoR)”
> “Assess progression free survival (PFS)”
> “Determine cystectomy free survival”
> “Assess the rate of delayed response beyond 3 months following treatment”
> “Evaluate the differential response in patients with persistent and relapsed disease”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.1-4"></a>

#### Expected benefit of the combination in the clinical study protocol

> “Both agents have demonstrated activity when used as single agents in NMIBC.”
> “It is anticipated that the combination may result in greater activity than either agent alone based on an augmented immune response to CG0070 in the presence of pembrolizumab.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="heading-3.1.3.2"></a>

### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

#### Study dates, enrollment, and sites in the ClinicalTrials.gov record

| Study characteristic | Quoted record |
| --- | --- |
| Study start (actual) | “2020-12-08” |
| Primary completion (actual) | “2023-03-07” |
| Study completion (actual) | “2024-05-28” |
| Enrollment (actual) | “35” |
| Sites | “This study has 19 locations” |

Source: [ClinicalTrials.gov NCT04387461](https://clinicaltrials.gov/study/NCT04387461)

<a id="topic-3.1.3.2-2"></a>

#### Enrollment by country in the published final results

| Country | Participants, n (%) |
| --- | --- |
| USA | “30 (85.7)” |
| Korea | “5 (14.3)” |

Source: [Nature Medicine CORE-001 article Table 1 (2024)](https://www.nature.com/articles/s41591-024-03025-3/tables/1)

<a id="topic-3.1.3.2-3"></a>

#### Planned accrual period and end of long-term follow-up in the clinical study protocol

> “Study accrual is expected to occur over a period of 24 months, therefore the time from the start of accrual to the last patient visit is estimated at 48 months.”
> “Under Protocol Amendment 7, no additional Long-Term Efficacy Follow-Up assessments will be completed, and no additional Long-Term Efficacy Follow-Up data will be collected.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.2-4"></a>

#### Data cutoffs for the final results

> “As of the data cutoff on February 5, 2024, the CR rate in the intention-to-treat (ITT) population at 12-months and any time, was 57% (20/35) [95% confidence interval (CI), 40-73%] and 83% (29/35) (95% CI, 70-95%), respectively.”
> “As of May 17, 2024, the CR rate in the ITT population at 24 months was 54% (19/35) (95% CI, 37-71%).”

Source: [CG Oncology CORE-001 final results press release (2024)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-present-positive-final-results-phase-2-core-001)

<a id="topic-3.1.3.2-5"></a>

#### Publication and congress presentation of the final results

> “The most recent data cut as of May 17, 2024, was also featured as a poster at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.”

Source: [CG Oncology CORE-001 Nature Medicine publication press release (2024)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-announces-nature-medicine-publication-final-results)

<a id="heading-3.1.3.3"></a>

### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

#### Single-arm, open-label design in the ClinicalTrials.gov record

| Design characteristic | Quoted record |
| --- | --- |
| Phase | “Phase 2” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Collaborator | “Merck Sharp & Dohme LLC” |

Source: [ClinicalTrials.gov NCT04387461](https://clinicaltrials.gov/study/NCT04387461)

<a id="topic-3.1.3.3-2"></a>

#### Design overview and safety lead-in cohort in the clinical study protocol

> “This is a Phase 2, open-label, trial designed to evaluate CG0070 and DDM in combination with pembrolizumab in patients with NMIBC who have failed prior BCG therapy.”
> “Up to 35 patients with CIS with or without concomitant TaHG or T1 papillary disease will be enrolled.”
> “For the purposes of establishing the safety of CG0070 combined with pembrolizumab, the initial 10 patients will be considered a ‘lead in cohort’.”
> “Thereafter, an additional 25 patients will be enrolled.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.3-3"></a>

#### Disease assessments and central review in the clinical study protocol

> “While on study treatment, all patients will undergo urine cytology and cystoscopy with directed biopsy of any suspicious lesions every 12 weeks for up to 2 years.”
> “In all patients, an upper urinary tract evaluation utilizing CT urogram or MRU will be performed every 48 weeks on study.”
> “Central review of safety laboratory, cytology, pathology, and radiographic studies will be completed for all patients.”
> “During Long-Term Efficacy Follow-Up, response assessments will be based on local review.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.3-4"></a>

#### Trial design and Merck supply agreement in the annual report

> “CORE-001 was a Phase 2 single-arm, open-label clinical trial of cretostimogene administered in up to 35 patients with high-risk BCG-unresponsive NMIBC that have CIS-containing tumors, in combination with pembrolizumab, following disease resection.”
> “We entered into a clinical trial collaboration and supply agreement with Merck providing at no-cost supply of pembrolizumab for use in CORE-001 (which agreement also provides for the joint ownership of clinical trial data but has no additional financial obligations and terminates upon conclusion of the trial).”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-3.1.3.4"></a>

### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

#### Key inclusion criteria in the clinical study protocol

> “Be ≥18 years of age (or legal age of majority in the jurisdiction) on day of signing informed consent.”
> “Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.”
> “Relapsed or persistent CIS (with or without TaHG or T1 disease) within 12 months of the completion (last dose) of adequate BCG treatment for HGUC (e.g., CIS, TaHG, T1, or a combination of these HGUC pathologies).”
> “Pathological confirmation of BCG unresponsive CIS within 10 weeks of study enrollment.”
> “CIS specimen must be predominantly urothelial (transitional cell) and have less than 50% variant (e.g., sarcomatoid, squamous etc. component) histology.”
> “Have all Ta and/or T1 disease resected and all CIS resected or fulgurated, as feasible, prior to study treatment (e.g., prior to Day 1 treatment).”
> “At least 5 of 6 doses of an initial induction course (adequate induction) plus at least 2 of 3 doses of maintenance therapy, OR”
> “At least 5 of 6 doses of an initial induction course (adequate induction) plus at least 2 of 6 doses of a second induction course.”
> “Ineligible to receive radical cystectomy (medically unfit) or refusal of radical cystectomy based on Investigator assessment.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.4-2"></a>

#### Key exclusion criteria in the clinical study protocol

> “Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137)”
> “Has current or past history of muscle invasive (T2 or higher stage) or locally advanced (T3/T4, any N) or metastatic bladder cancer”
> “Has had prior treatment with any human adenovirus serotype 5 based therapy (e.g., Ad-interferon or Instiladrin)”
> “Has significant immunodeficiency due to underlying illness (e.g., known HIV/AIDS)”
> “Has active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs).”
> “Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis”
> “Cannot tolerate study-related biopsies, IVE administration, or 1-hour bladder hold of CG0070.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.4-3"></a>

#### Definition of BCG-unresponsive disease and the 15-month assessment window in the ClinicalTrials.gov record

> “Unresponsive to prior BCG therapy (Lerner 2015) defined as persistent or recurrent CIS alone or with recurrent Ta/T1 (noninvasive papillary disease/tumor invades the sub- epithelial connective tissue) disease within 12 months of completion of adequate BCG therapy.”
> “An assessment within 15 months can also qualify when no assessment was performed within 12 months after completion of adequate BCG therapy.”
> “Adequate BCG is defined as at least 5 treatments with induction BCG followed by at least 2 BCG treatments as reinduction or maintenance”
> “Prior therapy with or intolerant to prior checkpoint inhibitor therapy”

Source: [ClinicalTrials.gov NCT04387461](https://clinicaltrials.gov/study/NCT04387461)

<a id="topic-3.1.3.4-4"></a>

#### FDA guidance as the basis of the BCG-unresponsive definition in the clinical study protocol

> “The definition of BCG unresponsive disease will follow the standard U.S. Food and Drug Administration (FDA) guidance document”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="heading-3.1.3.5"></a>

### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

#### Treatment schedule in the published final results

> “Thirty-five patients were treated with intravesical cretostimogene with systemic pembrolizumab.”
> “Induction cretostimogene was administered weekly for 6 weeks followed by three weekly maintenance infusions at months 3, 6, 9, 12 and 18 in patients maintaining complete response (CR).”
> “Patients with persistent CIS/high-grade Ta at the 3-month assessment were eligible for re-induction.”
> “Pembrolizumab was administered for up to 24 months.”

Source: [Li et al. (2024a)](https://www.nature.com/articles/s41591-024-03025-3)

<a id="topic-3.1.3.5-2"></a>

#### Cretostimogene dose and schedule in the clinical study protocol

> “CG0070 will be administered at a dose of 1 × 1012 viral particles (vp) intravesically (IVE) following a sequence of bladder washes with 5% DDM and normal saline.”
> “If the patient has persistent CIS, TaHG, or CIS with TaHG at Week 13, the patient will receive another cycle of 6 weekly treatments on Weeks 13, 14, 15, 16, 17, and 18.”
> “If there is no disease present at Week 13 (e.g., the patient has a complete response), the patient will receive 3 weekly treatments on Weeks 13, 14, and 15.”
> “Beginning at Week 25, all patients will receive 3 weekly treatment cycles every 12 weeks through Week 51 then a last treatment cycle of CG0070 at Weeks 73, 74, and 75 until either the patient discontinues from the study treatment or after 24 months.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.5-3"></a>

#### Bladder wash and instillation procedure with DDM in the clinical study protocol

> “Initial bladder wash with 100 mL normal saline”
> “Second bladder wash with 75 mL 0.1% DDM”
> “Instillation of 100 mL 0.1% DDM for 15 minutes (±5 minutes)”
> “Third bladder wash with 100 mL of normal saline”
> “Instillation of 100 mL CG0070 in normal saline (within 30 minutes [±5 minutes] of initial saline wash) with 1 hour dwell time (±5 minutes) from time of complete instillation”
> “Patients will be monitored for at least 1 hour following IVE treatment to observe safety and collect protocol specified research samples”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.5-4"></a>

#### Pembrolizumab dose and transition from every-3-week dosing in the clinical study protocol

> “Pembrolizumab 400 mg IV will be given concurrently starting on Day 1 and continue every 6 weeks for a completion of 18 administrations (approximately 2 years)”
> “As applicable, for patients started on 200 mg IV every 3 weeks (under the initial trial design), transition to 400 mg IV every 6 weeks will commence at Weeks 7, 13, 19, 25 etc. (e.g., at 6-week intervals from initiation of pembrolizumab).”
> “A 400 mg Q6W dosing regimen of pembrolizumab is expected to have a similar benefit-risk profile as 200 mg Q3W, in all treatment settings in which 200 mg Q3W pembrolizumab is currently appropriate (Lala 2020).”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.5-5"></a>

#### Treatment arm in the ClinicalTrials.gov record

> “CG0070 will be administered intravesically (IVE) following a sequence of bladder washes with 5% DDM and normal saline.”
> “Beginning at Week 25, patients will receive weekly x 3 treatments every 3 months through Week 49 then every 24 weeks thereafter.”
> “Pembrolizumab will be given intravenous (IV) concurrently starting on Day 1 and continue every 6 weeks for up to 2 years.”
> “Transduction-enhancing agent.”

Source: [ClinicalTrials.gov NCT04387461](https://clinicaltrials.gov/study/NCT04387461)

<a id="topic-3.1.3.5-6"></a>

#### Dose concentration and dosing schedule in the annual report

> “Patients that demonstrate a CR after an initial six-week induction phase of weekly cretostimogene administrations, dosed at a concentration of 1x1012 VP per milliliter, who also receive two, 400 mg doses of pembrolizumab over three months, are given a maintenance course of three weekly doses of cretostimogene at an equivalent VP concentration, along with two doses of pembrolizumab for three months.”
> “The dosing schedule of intravesical cretostimogene in CORE-001 is similar to BOND-003, while pembrolizumab is administered pursuant to its approved dosing schedule.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-3.1.3.6"></a>

### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

#### 3.1.3.6.1 Rationale for Using Complete Response at 12 Months as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

##### Primary and secondary endpoints in the published final results

> “The primary endpoint was CR at 12 months as assessed by cystoscopy, urine cytology, cross-sectional imaging and mandatory bladder mapping biopsies.”
> “Secondary endpoints included CR at any time, duration of response, progression-free survival and safety.”

Source: [Li et al. (2024a)](https://www.nature.com/articles/s41591-024-03025-3)

<a id="topic-3.1.3.6.1-2"></a>

##### Primary outcome in the ClinicalTrials.gov record

> “Complete response rate in patients”
> “Percentage of patients with a complete response as defined by FDA guidance document dated February 2018 for NMIBC.”

Source: [ClinicalTrials.gov NCT04387461](https://clinicaltrials.gov/study/NCT04387461)

<a id="topic-3.1.3.6.1-3"></a>

##### Mandatory bladder mapping at 12 months in the clinical study protocol

> “At Week 49, in addition to the assessment of urine cytology, cystoscopy, directed biopsy, and CTU urogram/MRU, mandatory bladder mapping (random biopsy of the trigone, bladder dome, right, left, and posterior bladder walls and a prostatic urethra biopsy [prostatic urethra biopsy required in males with prior documented involvement]) will be conducted to assess disease status and confirm complete response.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.6.1-4"></a>

##### Definition of complete response in the clinical study protocol

> “Notably, low-grade disease will not be regarded as non-response for the purposes of assessing complete response in this study.”
> “Negative cystoscopy, negative urine cytology (NOTE: atypical cytology will be regarded as negative), and negative biopsy as appropriate (e.g., biopsy of areas on cystoscopy suspicious for malignancy at 12-week assessments)”
> “Positive cystoscopy with biopsy-proven benign or low-grade NMIBC and negative cytology (or positive cytology if found in conjunction with low-grade NMIBC)”
> “Positive (malignant or suspicious) cytology in the absence of an identifiable source”
> “Urothelial carcinoma of the upper tract, prostatic urethra, or other extra-vesicular disease will count as non-response.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.6.1-5"></a>

##### Historical 12-month complete response rates cited as the basis for the null hypothesis in the clinical study protocol

> “For the purpose of study design, a complete response rate at 12 months of 19% (H0) for the experimental regimen in this setting will not be viewed as compelling for further study while a complete response rate of 36% (Ha) or more will be considered of interest for further investigation.”
> “The overall response rate at any time was 41% and duration of response (DoR) was 16.2 months, while the response rate at 12 months was estimated at ~20%.”
> “The complete response rate was 51%, the median duration of response was 9.7 months, and 46% of responding patients remained in complete response for at least one year (Adstiladrin [nadofaragene firadenovec-vncg] USPI 2022).”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.6.1-6"></a>

##### Complete response rate with duration of response as the single-arm endpoint in FDA guidance

> “The primary efficacy endpoint in single-arm trials of patients with BCG-unresponsive NMIBC should be the complete response rate in patients with CIS.”
> “Sponsors should consider the complete response rate in the context of the duration of response.”
> “A high complete response rate is not meaningful if the response duration is short.”

Source: [FDA BCG-unresponsive NMIBC guidance (2018)](https://digirepo.nlm.nih.gov/master/borndig/101733968/UCM529600.pdf)

<a id="topic-3.1.3.6.1-7"></a>

##### Clinically meaningful durable response rate at 12 months in International Bladder Cancer Group recommendations

> “BCG-unresponsive CIS: an initial CR rate of 50% at 6 months and a durable response rate of 30% at 12 months and 25% at 18 months would be clinically meaningful”

Source: [Kamat et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5321095/)

<a id="topic-3.1.3.6.1-8"></a>

##### Secondary endpoints in the clinical study protocol

> “Safety of CG0070 and pembrolizumab (AEs) including incidence, severity and relationship using CTCAE version 5.0”
> “Complete response rate at any time”
> “Duration of response”
> “Cystectomy free survival”
> “Progression free survival”
> “Overall survival”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.6.1-9"></a>

##### Exploratory endpoints including viral shedding in the clinical study protocol

> “Evaluate anti-tumor and anti-viral immune response including assessment of immune response in the peripheral blood, urine, and tumor microenvironment”
> “Evaluate tumor PD-L1, E2F transcription factor, and CAR expression”
> “Evaluate urine, blood, saliva, and tissue levels of CG0070”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="heading-3.1.3.7"></a>

### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

#### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

##### Sample size calculation in the clinical study protocol

> “The statistical design is a single-stage design using a standard 1-sided normal statistical test of a single binomial proportion with no interim analysis.”
> “The primary analysis will test H0: π ≤0.19 versus Ha: π >0.19 using a single proportion asymptotic normal test statistic, at alpha 1-sided 0.10.”
> “With the specified sample size there will be approximately 81% power for this test if the true population proportion is 36%.”
> “Using these operating characteristics for study design, a total of 30 evaluable patients will be accrued.”
> “If ≥9/30 have a complete response, H0 will be rejected and activity at least at 36% response rate concluded.”
> “Finally, an additional 5 patients may be added to account for potential non-evaluable patients (e.g., lost to follow-up or withdrawal of consent prior to the first response assessment) resulting in a total patient number of 35.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.7.1-2"></a>

##### Target and actual enrollment in the ClinicalTrials.gov record

> “The target population of 37 subjects with CIS with or without concomitant high-grade Ta or T1 papillary disease will be enrolled.”
> “Enrollment (Actual) 35”

Source: [ClinicalTrials.gov NCT04387461](https://clinicaltrials.gov/study/NCT04387461)

<a id="topic-3.1.3.7.1-3"></a>

##### Participants treated and analyzed in the published final results

> “Thirty-five patients were treated with intravesical cretostimogene with systemic pembrolizumab.”
> “The CR rate in the intention-to-treat population at 12 months was 57.1% (20 out of 35, 95% confidence interval (CI) 40.7–73.5%), meeting the primary endpoint.”

Source: [Li et al. (2024a)](https://www.nature.com/articles/s41591-024-03025-3)

<a id="heading-3.1.3.7.2"></a>

#### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

##### Analysis populations in the clinical study protocol

> “Enrolled: All patients who have provided informed consent, met all inclusion criteria, and are enrolled in the study”
> “All Treated: All patients who receive at least one dose of CG0070.”
> “Efficacy-Evaluable: All patients who have received at least one dose of CG0070, met the definition of BCG-unresponsive NMIBC at baseline, and completed protocol-specified efficacy assessments post-baseline”
> “Efficacy will be presented as the percentage of patients with complete response within the Enrolled and Efficacy-Evaluable analysis populations.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.7.2-2"></a>

##### Handling of participants without a 12-month assessment and time-to-event methods in the clinical study protocol

> “Patients who complete the initial study specified response assessment but fail to reach the 12-month evaluation for response will be considered non-complete responders.”
> “Time based endpoints (e.g., disease free survival, duration of response, time to cystectomy, time to progression, disease-specific survival, overall survival) will be displayed using Kaplan Meier statistics.”
> “Analyses performed for this study will utilize descriptive statistics.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.7.2-3"></a>

##### Safety analysis methods in the clinical study protocol

> “The incidence of all AEs will be tabulated and classified by system organ class and preferred term using the Medical Dictionary for Regulatory Activities (MedDRA).”
> “For incidence reporting, if a patient reported more than one AE that was coded to the same system organ class or preferred term, the patient will be counted only once at the highest observed grade for that specific system organ class or preferred term.”
> “Treatment emergent AEs will be captured from Day 1 through 30 days after the last treatment with CG0070 or pembrolizumab; however, SAEs resulting from a screening procedure will also be captured.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.7.2-4"></a>

##### Evaluable-patient denominators in the annual report

> “Moreover, administration of cretostimogene has also resulted in durable responses, with 81.8% (n=27/33) of the evaluable patients maintaining a CR at six months and 68.0% (n=17/25) of evaluable patients maintaining a CR at 12 months, each as of the cutoff date.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="heading-3.1.3.8"></a>

### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

#### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

##### Reasons for discontinuation without disease recurrence

| Participant ID | Dropout study timepoint | Primary reason |
| --- | --- | --- |
| 1113002 | “Month 3” | “Patient discontinued the study prior to completion of all the required protocol evaluations at 3-months (with no evidence of disease recurrence)” |
| 1101006 | “Month 6” | “Complete Response at Month 3; death of non-bladder related reasons (with no evidence of treatment toxicity or disease recurrence)” |
| 1117001 | “Month 9” | “Complete Response at Month 6; withdrew from study due to comorbidities unrelated to study treatment (with no evidence of disease recurrence)” |
| 1110004 | “Month 9” | “Complete Response at Month 6; withdrew consent from further treatment (with no evidence of disease recurrence)” |
| 1204001 | “Month 12” | “Complete Response at Month 9; patient withdrew consent from further treatment and efficacy evaluations (with no evidence of disease recurrence)” |
| 1206001 | “Month 15” | “Complete Response through Month 12; patient withdrew consent from further treatment and efficacy evaluations (with no evidence of disease recurrence)” |

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.8.1-2"></a>

##### Reasons for screen failure

| Participant ID | Entry criterion not met | Details |
| --- | --- | --- |
| 1105001 | “EXCLUSION 15” | “Has a known additional malignancy that is progressing or has required active treatment within the past 3 years” |
| 1116001 | “INCLUSION 10” | “Patients must be willing to comply with study mandated cystoscopies, urine cytology, urograms, biopsies, and other procedures” |
| 1118001 | “INCLUSION 4” | “Have all Ta and/or T1 disease resected and all CIS resected or fulgurated, as feasible, prior to study treatment” |
| 1101005 | “INCLUSION 3” | “CIS unresponsive to prior BCG therapy.” |
| 1115004 | “INCLUSION 5” | “Received prior adequate BCG therapy as defined per protocol” |
| 1102001 | “INCLUSION 3” | “CIS unresponsive to prior BCG therapy.” |
| 1117002 | “INCLUSION 3” | “CIS unresponsive to prior BCG therapy.” |
| 1101009 | “INCLUSION 3” | “CIS unresponsive to prior BCG therapy.” |
| 1101012 | “INCLUSION 3” | “CIS unresponsive to prior BCG therapy.” |

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="heading-3.1.3.8.2"></a>

#### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

##### Baseline characteristics in the published final results

| Characteristic | n = 35 |
| --- | --- |
| Age, median | “72” |
| Age, range | “57–90” |
| Sex, male | “33 (94.3)” |
| Sex, female | “2 (5.7)” |
| ECOG 0 | “25 (71.4)” |
| ECOG 1 | “9 (25.7)” |
| ECOG 2 | “1 (2.9)” |
| Race, White | “27 (77.1)” |
| Race, Black/African American | “2 (5.7)” |
| Race, Asian | “5 (14.3)” |
| Race, unknown | “1 (2.9)” |
| Stage, CIS | “27 (77.1)” |
| Stage, CIS + high-grade Ta | “4 (11.4)” |
| Stage, CIS + high-grade T1 | “4 (11.4)” |
| Prior BCG courses, 2 | “18 (51.4)” |
| Prior BCG courses, 3 | “8 (22.9)” |
| Prior BCG courses, 4 | “2 (5.7)” |
| Prior BCG courses, 5 | “4 (11.4)” |
| Prior BCG courses, ≥6 | “3 (8.6)” |

Source: [Nature Medicine CORE-001 article Table 1 (2024)](https://www.nature.com/articles/s41591-024-03025-3/tables/1)

<a id="topic-3.1.3.8.2-2"></a>

##### Prior BCG instillations and persistent or recurrent disease in the interim presentation

| Characteristic | Quoted value |
| --- | --- |
| Number of prior BCG instillations, median (range) | “12 (9 - 30)” |
| Persistent high-risk NMIBC, n | “21” |
| Persistent high-risk NMIBC, % | “60” |
| Recurrent high-risk NMIBC, n | “14” |
| Recurrent high-risk NMIBC, % | “40” |

Source: [Li et al. (2023)](https://cgoncology.com/wp-content/uploads/2025/11/AUA-2023-CORE-001-Presentation.pdf)

<a id="topic-3.1.3.8.2-3"></a>

##### Participants enrolled at U.S. sites in a pooled demographic analysis

> “Retrospective analysis of HR BCG-UR NMIBC patients enrolled from BOND-003 (n=71) and CORE-001 (n=30) across U.S. based sites”
> “Enrollment characteristics across two cretostimogene studies with HR BCG-UR NMIBC demonstrate a generalizable racial, ethnic, and gender distribution”

Source: [Lotan et al. (2025)](https://cgoncology.com/wp-content/uploads/2025/11/SCSAUA_Lotan_007_Clinical-Trials-Demographics-1-1.pdf)

<a id="heading-3.1.3.8.3"></a>

#### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

##### Complete response at 12 months, 3 months, and 24 months in the published final results

> “The CR rate in the intention-to-treat population at 12 months was 57.1% (20 out of 35, 95% confidence interval (CI) 40.7–73.5%), meeting the primary endpoint.”
> “A total of 29 out of 35 patients (82.9%, 95% CI 70.4–95.3%) derived a CR at 3 months.”
> “With a median follow-up of 26.5 months, the median duration of response has not been reached (95% CI 15.7 to not reached).”
> “The CR rate at 24 months was 51.4% (18 out of 35) (95% CI 34.9–68.0%).”
> “No patient progressed to muscle-invasive bladder cancer in this trial.”

Source: [Li et al. (2024a)](https://www.nature.com/articles/s41591-024-03025-3)

<a id="topic-3.1.3.8.3-2"></a>

##### Final results at the May 17, 2024 data cutoff: response durability, Kaplan-Meier estimates, progression-free and cystectomy-free survival

> “As of the data cutoff on February 5, 2024, the CR rate in the intention-to-treat (ITT) population at 12-months and any time, was 57% (20/35) [95% confidence interval (CI), 40-73%] and 83% (29/35) (95% CI, 70-95%), respectively.”
> “As of May 17, 2024, the CR rate in the ITT population at 24 months was 54% (19/35) (95% CI, 37-71%).”
> “Of the patients in a CR at 12 months, 95% of patients (19/20) maintained a CR for another 12 months.”
> “Median DoR has not been reached but exceeds 21 months.”
> “Additionally, the Kaplan-Meier estimates for CR rate at 12 and 24 months were 77.3% (95% CI, 58.1-88.5%) and 69.6% (95% CI, 49.4-83.0%), respectively.”
> “Progression-free survival (PFS) at 24 months is 100% with no patients progressing to muscle invasive cancer or metastatic disease; Cystectomy-free survival (CFS) at 24 months was 80%; for patients in CR, CFS at 24 months was 100%.”

Source: [CG Oncology CORE-001 final results press release (2024)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-present-positive-final-results-phase-2-core-001)

<a id="topic-3.1.3.8.3-3"></a>

##### Complete response at any time, 12 months, and 24 months in the annual report

> “Final results from the CORE-001 demonstrated that, as of the May 17, 2024 data cutoff, 29 of the 35 (82.9%; 95% CI, 70.4-95.3%) evaluable patients displayed a CR at any time subsequent to completion of induction therapy.”
> “As of the May 17, 2024 data cutoff, 29 of the 35 (82.9%; 95% CI, 70.4-95.3%) patients achieved a CR at any time, with 57.1% (n=20/35, 95% CI, 39.5-73.2%) of patients maintaining a CR at 12 months, and 54.3% (n=19/35, 95% CI, 36.9-70.8%) of patients maintaining a CR at 24 months, indicating that 95.1% of patients in CR at 12 months remain in CR at 24 months.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-3.1.3.8.3-4"></a>

##### Correction to the key of the duration-of-response figure

> “In the version of the article initially published, in the key to Fig. 2b, the red diamond representing “Recurrence/NR” has been corrected to a green diamond to match the graph.”

Source: [Nature Medicine CORE-001 publisher correction (2024)](https://www.nature.com/articles/s41591-024-03157-6)

<a id="topic-3.1.3.8.3-5"></a>

##### Exploratory urinary minimal residual disease analysis across BOND-003 and CORE-001

> “UroAmp stratified patients treated with Cretostimogene as MRD positive or negative and was associated with durable 12 mo. RFS.”
> “Longitudinal MRD assessment may be able to support the stratification of treatment escalation or de-escalation in future clinical trials.”

Source: [Mokkapati (2025)](https://cgoncology.com/wp-content/uploads/2025/11/A0793_Mokkapati_EAU-2025_BOND-003-and-CORE-001-Convergent_Final-V7-1.pdf)

Additional sources: [Li et al. (2024b)](https://cgoncology.com/wp-content/uploads/2025/11/REQ082_ASCO_2024_Roger-Li_CORE-001_Final_Website.pdf)

<a id="heading-3.1.3.8.4"></a>

#### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

#### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

##### Treatment-related adverse events in the published final results

> “Adverse events attributed to cretostimogene were low grade, self-limiting and predominantly limited to bladder-related symptoms.”
> “A total of 5 out of 35 patients (14.3%) developed grade 3 treatment-related adverse effects.”
> “There was no evidence of overlapping or synergistic toxicities.”

Source: [Li et al. (2024a)](https://www.nature.com/articles/s41591-024-03025-3)

<a id="topic-3.1.3.8.5-2"></a>

##### Treatment-related adverse effects by maximum severity

| Preferred term | Grade 1, n (%) | Grade 2, n (%) | Grade 3, n (%) | Total (N = 35), n (%) |
| --- | --- | --- | --- | --- |
| Participants with at least one study drug-related treatment-emergent adverse effect | “9 (25.7)” | “18 (51.4)” | “5 (14.3)” | “32 (91.4)” |
| Bladder spasm | “13 (37.1)” | “4 (11.4)” | “0” | “17 (48.6)” |
| Fatigue | “11 (31.4)” | “2 (5.7)” | “0” | “13 (37.1)” |
| Dysuria | “8 (22.9)” | “1 (2.9)” | “0” | “9 (25.7)” |
| Pollakiuria | “8 (22.9)” | “1 (2.9)” | “0” | “9 (25.7)” |
| Hematuria | “5 (14.3)” | “1 (2.9)” | “0” | “6 (17.1)” |
| Micturition urgency | “4 (11.4)” | “2 (5.7)” | “0” | “6 (17.1)” |
| Diarrhea | “4 (11.4)” | “0” | “1 (2.9)” | “5 (14.3)” |
| Nocturia | “3 (8.6)” | “1 (2.9)” | “0” | “4 (11.4)” |
| Hypothyroidism | “1 (2.9)” | “3 (8.6)” | “0” | “4 (11.4)” |
| Urinary tract infection | “3 (8.6)” | “1 (2.9)” | “0” | “4 (11.4)” |
| Blood alkaline phosphatase increased | “0” | “0” | “1 (2.9)” | “1 (2.9)” |
| Ejection fraction decreased | “0” | “0” | “1 (2.9)” | “1 (2.9)” |
| Neutrophil count decreased | “0” | “0” | “1 (2.9)” | “1 (2.9)” |
| Adrenal insufficiency | “0” | “0” | “1 (2.9)” | “1 (2.9)” |
| Immune-mediated hepatitis | “0” | “0” | “1 (2.9)” | “1 (2.9)” |

Source: [Nature Medicine CORE-001 article Table 2 (2024)](https://www.nature.com/articles/s41591-024-03025-3/tables/2)

<a id="topic-3.1.3.8.5-3"></a>

##### Attribution of grade 3 or higher events and table inclusion rules

> “The table presents study drug-related adverse effects that occurred in at least 10% or more of all treated patients (n = 35) and all study drug-related grade 3 events.”
> “AEs include all events that occurred or worsened after the first dose of cretostimogene or pembrolizumab.”
> “There were no grade 3–5 cretostimogene drug-related adverse effects.”
> “There were no grade 4–5 pembrolizumab drug-related adverse effects.”

Source: [Nature Medicine CORE-001 article Table 2 (2024)](https://www.nature.com/articles/s41591-024-03025-3/tables/2)

<a id="topic-3.1.3.8.5-4"></a>

##### Author correction removing attribution of immune-related adverse effects from the abstract

> “In the version of the article initially published, the text”
> “Immune-related adverse effects were exclusively associated with pembrolizumab”
> “and, in the following sentence, also referring to adverse effects,”
> “…all related to pembrolizumab”
> “has been removed from the Abstract.”
> “assessed by the treating physicians”
> “Related adverse effect to pembrolizumab…”

Source: [Nature Medicine CORE-001 author correction (2024)](https://www.nature.com/articles/s41591-024-03137-w)

<a id="topic-3.1.3.8.5-5"></a>

##### Safety summary in the annual report

> “The safety profile was favorable, with no overlapping or synergistic toxicity observed.”
> “Adverse events attributed to cretostimogene were Grade 1 or Grade 2 and self-limited.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-3.1.3.8.5-6"></a>

##### Grade 3 events and absence of grade 4 or 5 events in the interim presentation

> “Grade 3 AE included (4 total patients)”
> “Autoimmune hepatitis”
> “Reduced ejection fraction”
> “Neutrophil count decreased”
> “Alkaline phosphatase increased”
> “Adrenal insufficiency”
> “Grade 4 / 5 AE – none observed”

Source: [Li et al. (2023)](https://cgoncology.com/wp-content/uploads/2025/11/AUA-2023-CORE-001-Presentation.pdf)

<a id="topic-3.1.3.8.5-7"></a>

##### Adverse event grading and serious adverse event capture in the clinical study protocol

> “Serious adverse events (SAEs) will be captured from Day 1 through 90 days after the last treatment with CG0070 or pembrolizumab or, if the patient initiates new anticancer therapy, through 30 days after the last treatment with CG0070 or pembrolizumab.”
> “All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) and graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="heading-3.1.3.9"></a>

### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

#### Summary

CORE-001 was a single-arm, open-label phase 2 trial of 35 participants with no control arm, so the contribution of cretostimogene to the combination cannot be separated from that of pembrolizumab within the trial. The protocol tested a 12-month complete response rate of 19% (H0) against 36% (Ha) at a one-sided alpha of 0.10 with approximately 81% power, and required 30 evaluable participants. The 12-month complete response rate was 57.1% (20 of 35; 95% CI 40.7% to 73.5% in the publication and 39.5% to 73.2% in the annual report). The 24-month complete response rate was 51.4% (18 of 35) in the publication and 54% (19 of 35) at the later May 17, 2024 data cutoff reported by the company. Long-term efficacy and survival follow-up stopped under Protocol Amendment 7, so data beyond 24 months were not collected. Thirty of 35 participants (85.7%) were enrolled in the USA and 5 (14.3%) in Korea; 33 (94.3%) were male. Pembrolizumab dosing changed during the trial from 200 mg every 3 weeks to 400 mg every 6 weeks, and the DDM concentration is described as 5% in the protocol synopsis and registry record and as 0.1% in the protocol administration procedure. An author correction removed the abstract statements that attributed immune-related adverse effects exclusively to pembrolizumab, and added that attribution of adverse effects to pembrolizumab was “assessed by the treating physicians”. Long-term follow-up assessments were based on local review.

Source: [Li et al. (2024a)](https://www.nature.com/articles/s41591-024-03025-3); [Nature Medicine CORE-001 article Table 1 (2024)](https://www.nature.com/articles/s41591-024-03025-3/tables/1); [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf); [Nature Medicine CORE-001 author correction (2024)](https://www.nature.com/articles/s41591-024-03137-w); [CG Oncology CORE-001 final results press release (2024)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-present-positive-final-results-phase-2-core-001); [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm); [ClinicalTrials.gov NCT04387461](https://clinicaltrials.gov/study/NCT04387461)

<a id="topic-3.1.3.9-2"></a>

#### Discontinuation of long-term efficacy and survival follow-up under protocol amendment 7

> “Under Protocol Amendment 7, no additional Long-Term Efficacy Follow-Up assessments will be completed, and no additional Long-Term Efficacy Follow-Up data will be collected.”
> “Under Protocol Amendment 7, no additional Survival Follow-Up data will be collected.”

Source: [CG Oncology CORE-001 protocol (2024)](https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-024-03025-3/MediaObjects/41591_2024_3025_MOESM1_ESM.pdf)

<a id="topic-3.1.3.9-3"></a>

#### Additional patient data may differ from data at the cutoff

> “additional patient data related to cretostimogene in combination with pembrolizumab that continues to become available may be inconsistent with the data produced as of the data cutoff, and further analysis of existing data and analysis of new data may lead to conclusions different from those established as of the date hereof”

Source: [CG Oncology CORE-001 final results press release (2024)](https://ir.cgoncology.com/news-releases/news-release-details/cg-oncology-present-positive-final-results-phase-2-core-001)

<a id="topic-3.1.3.9-4"></a>

#### Single-arm trials appropriate only while no effective therapy is available in FDA guidance

> “If effective therapies become available in BCG-unresponsive NMIBC, a randomized trial may be appropriate.”

Source: [FDA BCG-unresponsive NMIBC guidance (2018)](https://digirepo.nlm.nih.gov/master/borndig/101733968/UCM529600.pdf)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
